Abstract Glial activation in the setting of central nervous system inflammation is a key feature of the multiple sclerosis (MS) pathology. Monitoring glial activation in subjects with MS, therefore, has the potential to be informative with respect to disease activity. The translocator protein 18 kDa (TSPO) is a promising biomarker of glial activation that can be imaged by positron emission tomography (PET). To characterize the in vivo TSPO expression in MS, we analyzed brain PET scans in subjects with MS and healthy volunteers in an observational study using [ 
Introduction
Glial activation in the setting of central nervous system (CNS) inflammatory demyelination is the pathologic hallmark of multiple sclerosis (MS). Activated microglia and reactive astrocytes not only augment CNS inflammation but may contribute to mechanisms of neurodegeneration such as glutamate excitotoxicity (Werner et al. 2001) and oxidative stress (Bagasra et al. 1995) . Therefore, monitoring glial activation in subjects with MS has the potential to be an informative measure of disease activity.
Translocator protein 18 kDa (TSPO), formerly termed the peripheral benzodiazepine receptor, has been imaged by positron emission tomography (PET) as a marker of glial activation. TSPO is an outer mitochondrial membrane protein involved in the control of steroidogenesis (McEnery et al. 1992) . During CNS inflammation, TSPO expression is increased in activated microglia, infiltrating macrophages and reactive astrocytes (Cosenza-Nashat et al. 2008 ). The TSPO-selective radioligand [ 11 C](R)-PK11195 has been studied in several neurologic disorders including MS. [ 11 C]PK11195 showed promise as a biomarker in MS, showing increased TSPO expression in areas of focal MS pathology defined by magnetic resonance imaging (MRI; Banati et al. 2000) . Newer TSPO-selective radioligands such as the aryloxyanilide-based [ 11 C]PBR28 has the potential to improve on these findings based on its higher brain uptake and specific binding (Kreisl et al. 2010) .
In this paper, we report the study of TSPO expression in subjects with MS by PET using the new selective radioligand [ Radioligand [ 11 C]PBR28 was produced in >99% radiochemical purity by 11 C-methylation of its O-desmethyl precursor, as originally described (Briard et al. 2008 ).
PET imaging with arterial blood sampling
The high-resolution research tomograph (HRRT; Siemens/ CPS, Knoxville, TN, USA) camera was used. The HRRT camera has a reconstructed resolution of 2.5 mm full-width half-maximum in all directions in 3-D mode. After injection of 650±92 MBq (specific activity at time of injection of 170±81 GBq/μmol) of [ 11 C]PBR28, PET scans were acquired for 120 to 150 min in 33 to 39 frames with scan duration ranging from 30 s to 5 min. As described previously, metabolite-corrected arterial input function was measured by blood sampling followed by radio-HPLC, and (Kreisl et al. 2010 ).
PET processing [ 11 C]PBR28 binding was measured in each voxel by calculating total distribution volume, V T using the Logan plot (Logan et al. 1990 ) and metabolite-corrected arterial input function based on 2-h brain and blood data. V T is brain activity normalized to plasma total (free plus protein-bound) [
11 C]PBR28 levels and corresponds to total (specific plus nondisplaceable) binding. Our previous study showed that 90-min data acquisition was adequate to measure [
11 C]PBR28 binding accurately (Fujita et al. 2008) . To be conservative, we used 2-h data for the analysis of all scans in the current study. For noisy data such as those in each voxel, the Logan plot is known to show smaller V T than compartmental models. Compartmental modeling is believed to be more resistant to errors caused by noise (Logan 2003) . We calculated V T in each voxel to allow inspection of V T values in all brain areas including those with and without changes in MRI by comparing the co-registered images. In gadolinium contrast-enhancing lesions, the Logan plot using voxel data showed only 9% smaller V T values than that based on region-of-interest data, and was therefore used as the primary method of PET analysis. To take into account inter-subject and between-scan variability in f P , V T was normalized to f P , and V T /f P was used as a measure of total binding of [ 11 C]PBR28. All PET processing was performed in PMOD software (PMOD Technologies Ltd., Zurich, Switzerland)
MRI acquisition
Subjects underwent a screening 1.5 T brain MRI. The exam included 2D T 1 -weighted spin echo; dual-echo fast spin-echo sequence providing both proton density and T 2 -weighted images; a T 2 -weighted fluid-attenuated inversion recovery (FLAIR) sequence; and three acquisitions of a 3-D inversion recovery prepared fast spoiled gradient echo (IR-FSPGR) sequence. In MS subjects, a second T 1 -weighted spin echo was performed after administration of a single-dose gadolinium gadopentate (Magnevist, Berlex Laboratories). All 2-D MRIs had 3 mm slice thickness whereas the 3-D IR-FSPGR had 1.2 mm slice thickness. Brain MRI was repeated for subjects with MS at the time of the PET scan (±7 days). Additional brain MRI covering the periods both before and after the PET scan was available for a number of subjects enrolled in longitudinal follow-up.
MRI processing
T 1 lesions were marked on the pre-contrast T 1 -weighted spinecho images by an investigator blinded to the PET imaging; a lesion was marked as such if it was hypointense on the T 1 -weighted images and hyperintense on the T 2 -weighted images. T 2 lesions were marked on the T 2 FLAIR images. Contrast-enhancing lesions were marked on the post-contrast T 1 -weighted spin-echo images. All lesion markings were done manually using Medical Image Processing, Analysis and Visualization. In addition, for each contrastenhancing lesion, we created a mask of contralateral normal-appearing white matter. Subsequently, all images and masks were registered to the PET scan using an affine transform with 6°of freedom, as implemented in Medical Imaging NetCDF tools. The three acquisitions of the 3-D IR-FSPGR sequence were registered and averaged in order to increase signal-to-noise ratio. Subsequently, they were segmented into gray matter, white matter, and cerebrospinal fluid using FAST (Zhang et al. 2001) . Segmented tissue masks were corrected for lesions. Subcortical structures were then segmented and individual masks for the thalamus, caudate, putamen, pallidum, nucleus accumbens, amygdala, and hippocampus were generated using FMRIB's Integrated Registration and Segmentation Tool. These masks were then used to further correct the gray and white matter masks. The resulting masks were registered to the PET image space using an affine transform with 6°of freedom, and were then used to calculate average [ 11 C]PBR28 binding values in lesions, white, and gray matter. The corrected masks were also used to calculate brain parenchymal and gray matter fraction as atrophy measures. Since direct comparison of absolute brain parenchymal volume between the patients and healthy control subjects may be obscured by differences in head size, particularly across sex and age, we normalized head size variability by using fractional gray matter volume and fractional white matter volume, which were computed as percentages of the intracranial volume; fractional gray matter ¼ gray matter= gray matterþ ð white matter þ CSFÞ. [ 11 C]PBR28 binding levels were compared between contrast-enhancing lesions and the contralateral NAWM by drawing the same size of region of interest on the parametric images where V T /f P values were calculated in each voxel using the Logan plot (i.e., V T /f P maps). [
11 C] PBR28 binding at periplaque white matter was assessed visually after multiplying the V T /f P maps with the segmented white matter mask and thresholding it to the level of average gray matter [ 11 C]PBR28 binding. The threshold provided normalization based on each individual patient's binding level similar to the one used by Versijpt and colleagues (Versijpt et al. 2005) .
Where interval PET scans were available on the same subject, the resulting V T /f P maps were registered using an affine transformation, and difference maps were calculated to identify regions of increased and decreased PBR binding.
Statistical analysis
The 11 C]PBR28 binding and MRI-defined lesions including gadolinium contrast-enhancing lesions, T 2 -hyperintense lesions and T 1 -hypointense lesions. Gadolinium contrast-enhancing lesions were identified on brain MRI of MS subjects. A total of ten MRI contrast-enhancing lesions were present in three subjects at the time of the PET scan. Contralateral NAWM was identified for comparison. Increased focal [ 11 C]PBR28 binding preceded the development of some gadolinium-enhancing lesions. This was shown in two MS subjects that developed new gadolinium contrast-enhancing lesions on a follow-up MRI 1 month after the PET scan. In one MS subject (MS5), a region of focal increased [ 11 C]PBR28 binding in an area of NAWM at the time of the PET scan corresponded to a contrast-enhancing lesion at a follow-up MRI exam 1 month later (Fig. 2d) . Similarly, in another subject (MS3), a region of increased [ 11 C]PBR28 binding corresponding to a non-enhancing T 1 -hypointense lesion preceded the development of new Fig. 1 .89) , or the MSFC z-score (p=0.68).
Discussion
The results of the [
11 C]PBR28 PET show altered compartmental distribution of TSPO expression in subjects with MS compared to healthy volunteers. The ratio of white matter fraction to gray matter fraction [
11 C]PBR28 binding was significantly elevated in MS, suggesting a change in the relative distribution of TSPO even though the global [11C]PBR28 binding was not significantly different between MS and healthy volunteers. This may be due to the fact that normalized parameters such as the ratio of white matter to gray matter fraction [
11 C]PBR28 binding are less noisy and more sensitive for detecting differences between groups. The increase in the ratio of white matter to gray matter TSPO expression could indicate either a relative increase in the white matter TSPO or a relative decrease in the gray matter TSPO in MS. Neither region showed statistically significant differences in [
11 C]PBR28 binding between MS and healthy volunteers when compared separately, thus, we could not conclusively attribute the increased ratio to changes in a single compartment.
Gadolinium contrast-enhancing lesions were associated with focal increases in [ 11 C]PBR28 binding. Areas corresponding to contrast-enhancing lesions were significantly higher with respect to [ 11 C]PBR28 binding than the contralateral NAWM, and the development of a new contrast-enhancing lesion on MRI was accompanied by interval increase in [ 11 C]PBR28 binding. The most likely source of increased TSPO expression in the contrastenhancing lesions of MS brain is activated microglia and macrophage (Katz et al. 1993) . The focal increase in TSPO expression detected by [
11 C]PBR28 PET that corresponds to and precedes the appearance of gadolinium enhancement on MRI may support a role for early microglial activation in the formation of some MS lesions. Although regions of increased [
11 C]PBR28 binding were not exclusively predictive of the development of new gadolinium-enhancing lesions, early glial activation in MS lesion formation is consistent with reports in the literature. Pathologic studies have shown evidence to suggest that microglial activation occurs very early in the formation of MS lesions, in some cases preceding lymphocytic infiltration and myelin loss (Henderson et al. 2009 ). Thus, differences in the temporal dynamics of contrast enhancement and the corresponding (Banati et al. 2000) , more recent studies have shown increased TSPO expression in reactive astrocytes as well. In particular, one study showed a temporal evolution in the cellular localization of TSPO in MS where TSPO expression was prominent in activated microglia/macrophage in active MS plaques, but was more prominent in reactive astrocytes in chronic MS plaques (Cosenza-Nashat et al. 2008) . Such findings suggest that the underlying process for increased TSPO in the early, inflammatory phase of MS may be different from that of the later chronic phase of MS.
The results of this [ 11 C]PBR28 PET study are consistent, in several respects, with results from the previous studies of TSPO using [ 11 C]PK11195. As was the case with [ 11 C] PBR28, among MRI-defined MS lesions, gadoliniumenhancing lesions showed the best correspondence with increased [
11 C]PK11195 binding (Banati et al. 2000; Debruyne et al. 2003) . There was poor correspondence (10-20%) between T 2 -hyperintense and T 1 -hypointense lesions and increased [ 11 C]PK11195 binding (Banati et al. 2000) . Global TSPO expression either did not differ significantly between groups of healthy volunteers and subjects with MS (Debruyne et al. 2003) , or only a minority demonstrated higher global TSPO expression in MS compared to healthy volunteers by [ 11 C]PK11195 PET (Banati et al. 2000) .
The small sample size was a limitation of this study. The study was not controlled for the use of disease modifying therapies in subjects with MS which could potentially confound the analysis of the relationship between [
11 C] PBR28 binding and measures of clinical disability. The study did, however, correct for differences in free plasma fraction of the radioligand. We have previously described low-affinity binding to [
11 C]PBR28 in about 10% of the subjects we have studied to date, and excluded two subjects with MS for the current study due to low-affinity binding (Kreisl et al. 2010) . In addition to low-affinity binders, Owen and colleagues recently identified another group of subjects that have mixed affinity-i.e., a mixture of highand low-affinity binding to [ 11 C]PBR28 (Owen et al. 2010 ). While this is potentially a confounding factor, it would not affect the comparisons carried out in this study that are within-subject or normalized. The strengths and the limitations of [ 11 C]PBR28 as a marker of TSPO in MS suggest that this radioligand could be utilized as a research tool to study the role of glial activation in the pathophysiology of MS. However, data is lacking at present with regard to the utility of [ 11 C]PBR28 as a biomarker in the clinical setting. Our results do not strongly support the role of [ 11 C]PBR28 as a predictive marker of disease progression in MS.
In summary, we report that [ 11 C]PBR28 PET shows altered distribution of brain TSPO expression in subjects with MS, characterized by increased ratio of white matter to gray matter fraction [
11 C]PBR28 binding. Focal increase in [ 11 C]PBR28 binding corresponded to areas of active CNS inflammation as defined by gadolinium contrast enhancement on MRI, and in some cases preceded the appearance of MRI contrast enhancement, suggesting that glial activation may be an early event in MS lesion formation. Global [ 11 C]PBR28 binding levels were higher in subjects with longer disease duration in MS, and may reflect accumulation of TSPO in activated microglia and reactive astrocytes.
